Vitamin K epoxide reductase (VKOR) generates vitamin K hydroquinone to sustain c-carboxylation of many blood coagulation factors. Here, we report the 3.6 Å crystal structure of a bacterial homologue of VKOR from Synechococcus sp. The structure shows VKOR in complex with its naturally fused redox partner, a thioredoxin-like domain, and corresponds to an arrested state of electron transfer. The catalytic core of VKOR is a four transmembrane helix bundle that surrounds a quinone, connected through an additional transmembrane segment with the periplasmic thioredoxin-like domain. We propose a pathway for how VKOR uses electrons from cysteines of newly synthesized proteins to reduce a quinone, a mechanism confirmed by in vitro reconstitution of vitamin K-dependent disulphide bridge formation. Our results have implications for the mechanism of the mammalian VKOR and explain how mutations can cause resistance to the VKOR inhibitor warfarin, the most commonly used oral anticoagulant.
Mammalian VKOR catalyses a decisive step in the vitamin K cycle ( Supplementary Fig. 1a ) that is required to sustain blood coagulation (reviewed in refs 1, 2) . The cycle occurs in the endoplasmic reticulum (ER) membrane and begins with the c-carboxylation of select glutamic acids in coagulation factors, a modification required for Ca 21 -dependent activation at sites of injury (reviewed in refs 3, 4) . The c-carboxylase requires vitamin K hydroquinone, which is oxidized to vitamin K epoxide. VKOR is necessary to regenerate the hydroquinone; VKOR reduces the epoxide in two steps, first to the quinone and then to the hydroquinone. The reducing equivalents have been proposed to come from protein disulphide isomerase (PDI), an ER-luminal enzyme with several thioredoxin (Trx)-like domains; PDI would in turn be reduced during disulphide bridge formation of newly synthesized proteins 5, 6 .
Both reaction steps catalysed by VKOR are inhibited by warfarin 7 (Supplementary Fig. 1b ), a drug that is widely used to treat thromboembolic diseases, including deep vein thrombosis, pulmonary embolism, stroke and myocardial infarction. One challenge of warfarin therapy is its narrow therapeutic window; overdose can cause severe haemorrhage that is often lethal. Genetic variation among patients causes significant differences in the required warfarin doses and has served as a model case for pharmacogenetic drug treatment 8 . Many warfarin resistance mutations map to VKORC1, the gene encoding VKOR 9 . However, how exactly warfarin inhibits VKOR is unclear.
Homologues of VKOR have been identified in a variety of organisms, including some plants, bacteria and archaea [10] [11] [12] (Supplementary Fig. 2 ). All homologues contain an active site CXXC motif, which in mammalian VKOR switches between reduced and disulphide-bonded states during the reaction cycle, as well as an additional pair of cysteines and a conserved serine/threonine. Bacterial VKOR homologues catalyse disulphide bridge formation in secreted proteins by cooperating with a periplasmic, Trx-like redox partner 11, 12 . In some species, a single polypeptide chain contains both VKOR and a Trx-like domain.
We have determined the crystal structure of such a natural fusion protein derived from Synechococcus sp., in which VKOR and its Trxlike partner are caught in an intermediate stage of the redox reaction.
The structure of this VKOR-complex not only sheds light on the redox pathway, but also has significant implications for the function of the mammalian counterpart and the mechanism by which VKOR mutations cause warfarin resistance. Because VKOR homologues are found in a number of medically important bacteria, including Mycobacterium tuberculosis 12 , our structure could also aid in the development of new antibiotics.
Structure of VKOR with its redox partner
The VKOR homologue from Synechococcus sp., naturally fused to a Trx-like domain, was expressed in Escherichia coli and purified in the detergent n-dodecyl-b-D-maltoside (DDM). The purified protein contained bound endogenous quinones, primarily ubiquinone (mass spectrometry data not shown), and showed a characteristic ultraviolet absorption at 400 nm 13 . Because the wild-type protein did not yield high-quality crystals, we tested mutants, in which cysteines were changed to alanines or serines to stabilize an interdomain disulphide bridge 14 . The VKOR domain mutant C56S gave crystals that belonged to the P6 1 space group ( Supplementary Table 1 ). Experimental phases with a maximum resolution of 3.6 Å were obtained by the multiple isomorphous replacement method and were markedly improved by solvent flattening due to the 80% solvent content. The membrane helices were well resolved in the resulting electron density map ( Supplementary Fig. 3 ), probably because they are packed side by side ( Supplementary Fig. 4 ). A model could be built with confidence, and the register was confirmed by the positions of aromatic residues and by specific binding sites of heavy atoms ( Supplementary Fig. 5a ). In addition, the positions of methionines were confirmed by crystallizing seleno-methionine substituted protein ( Supplementary Fig. 5b ). The Trx-like domain was also crystallized by itself; these crystals diffracted to 1.7 Å (Supplementary Table 1 ). The phases were obtained by the single-wavelength anomalous dispersion method using a mercury derivative and a model was built automatically ( Supplementary Fig. 6 ). The structure of the Trx-like domain docked well into the map of the full-length protein. The model of the complex of VKOR and its redox partner was refined to R work and R free factors of 24.6% and 30.5%, respectively. The model lacks the 15 amino-terminal and 5 carboxy-terminal residues of the full-length protein and has uncertainties in the region encompassing amino acids 53 to 55.
The protein consists of the membrane-embedded domain containing VKOR, connected via a linker segment to the extracellular Trx-like domain ( Fig. 1a ; see also Supplementary Movie 1). The membraneembedded part contains five transmembrane helices (TM) (Figs 1a, b). TMs 1-4 are homologous to human VKOR ( Supplementary Fig. 2 ; ,24% identical amino acids). Consistent with in vivo experiments 15 , both termini and a loop between TMs 2 and 3 are located in the cytosol. The helices form a four-helix bundle with a quinone in its interior. The quinone is close to the periplasmic side of the membrane, in proximity to the CXXC active site motif in TM4 (formed by Cys 130 and Cys 133). TM5 passes through the membrane to connect with the fused periplasmic Trx-like domain. TM5 is located on the outside of the four-helix bundle, contacting TM3 ( Fig. 1b ) and the loop between TM1 and 2.
The longest loop between TMs is on the periplasmic side of the VKOR homologue, between TM1 and TM2. This 1/2-loop contains an extended N-terminal part (called the '1/2-segment'), a short helix (called the '1/2-helix'), and a C-terminal segment that contacts TM5 (Fig. 1a ). The 1/2-segment contains a pair of cysteines (Cys 50 and Cys 56), which are present in all VKORs. The 1/2-helix begins after Cys 56 and ends with the conserved serine/threonine residue (Ser 62). In most species, there are five residues between the second cysteine and the conserved serine/threonine ( Supplementary Fig. 2 ), indicating that the 1/2-helix is a common feature. The 1/2-helix forms a lid on the four-helix bundle, shielding the quinone from the periplasmic space. The helix is amphipathic and likely lies on top of the lipid surface, with the well-conserved Trp 64 as a major anchor point.
Consistent with the introduced mutation Cys56Ser, an interdomain disulphide bridge with strong density at 3.5s is observed between Cys 50 in the VKOR domain and Cys 209 in the CXXC motif of the Trx-like domain. Formation of the inter-domain disulphide bridge is facilitated by the insertion of the 1/2-segment of VKOR into the active site groove of the Trx-like domain ( Supplementary Fig. 7 ). This groove is formed by several loops between the secondary structure elements, has a hydrophobic surface, and contains the active site CXXC motif. The groove likely also interacts with newly synthesized protein substrates, allowing disulphide exchanges. The Trx-like domain also contains two other cysteines (Cys 231 and Cys 244), which are disulphide-bonded and probably have a structural role.
The plane of the quinone ring is clearly defined ( Fig. 2a ; see also Supplementary Fig. 8 and Supplementary Movie 2), tilted by 70u with respect to the membrane surface. Much of the isoprenyl tail of the ubiquinone can also be seen, intercalated into the V-shaped cleft between TMs 2 and 3 (Fig. 2b) . The location of the isoprenyl tail establishes the positions of the substituents on the quinone ring ( Fig. 2a ; for chemical structure, see Supplementary Fig. 1b ). Strong, continuous density is observed in the ,2 Å gap between the C1 position of ubiquinone and Cys 133 in the CXXC motif of VKOR, indicating that they are linked by a covalent bond. Cys 130 and Cys 133 are located at the side of the quinone ring and there is strong density between the two sulphur atoms. It thus seems that the structure corresponds to a situation in which electrons are shared between the disulphide bridge in the CXXC motif and the quinone ring.
Implications for the mammalian VKOR
Although a three-TM model has been proposed for human VKOR 16 , our structure and multiple sequence alignments predict that the core of all VKORs, including those in mammals, consist of four TMs 10 ( Supplementary Fig. 2 ). This topology model places all enzymatically important residues on or close to the extracellular/luminal side of the membrane. These residues include the active site CXXC motif, the conserved serine/threonine in the 1/2-helix, and the two cysteines in the 1/2-segment. This topology would allow transfer of reducing equivalents from the Trx-like redox partner via the loop cysteines to the quinone in VKOR (see below).
The structure allows us to understand how mutations in the mammalian VKOR can cause warfarin resistance, particularly because warfarin-resistance mutations selected in a bacterial VKOR homologue map to the same residues 15 . There are eleven confirmed mutations in mammalian VKORs 9,17 , eight of which map close to the binding site of the quinone (Fig. 3a, b ). These include mutations of Val 29, Arg 33 and Asp 36 in TM1 (numbering for the human VKOR), Arg 58 and Trp 59 on the 1/2-helix, Leu 120 and Leu 128 in TM3, as well as Tyr 139 in TM4, a residue that has been implicated in warfarin binding 2, 18 . The striking clustering of the mutations indicates that warfarin binds to the same site as the quinone seen in our structure, or at least close to it (Fig. 3b ). The binding pocket is large enough to accommodate either the naphthoquinone vitamin K or warfarin, but not both, indicating that warfarin replaces vitamin K to cause inhibition. Some of the mutations around the quinone-binding site (Tyr139Phe (refs 2, Our structure supports the idea that the ER luminal redox partner of the mammalian VKOR is a Trx-like protein. Although there is a whole family of such proteins in the ER lumen, PDI is proposed to be the partner of VKOR 5, 6 . In this case, the first Trx-like domain of the enzyme (a-domain) would likely be responsible for the interaction, as it contains an active site CXXC motif and is the only thioredoxin fold of PDI that can be superimposed onto our structure without causing significant parts of the molecule to clash with the membrane (Supplementary Fig. 9 ). Because the Trx-like protein in the ER lumen ultimately donates its disulphide bridge to newly synthesized proteins, it is possible that VKOR or an uncharacterized VKOR-like protein 9 may contribute more generally to disulphide bond formation, even when uncoupled from its better characterized role in c-carboxylation.
Electron transfer pathway
Our structure corresponds to an arrested intermediate during the transfer of electrons from the Trx-like domain to the VKOR. The disulphide bridge between Cys 209 of the Trx-like domain and Cys 50 of VKOR would normally be transient, as it would be resolved by the formation of a disulphide bond between Cys 50 and Cys 56 (confirmed by mass spectrometry of the wild-type protein). In our structure, this step is prevented by mutation of Cys 56.
We propose the following pathway of electron transfer, which would be applicable to all VKORs (Fig. 4) . First, a newly synthesized protein reduces the CXXC motif of the Trx-like protein in the periplasm/ER lumen. Second, the Trx-like protein reduces the disulphide bridge between Cys 50 and Cys 56 in the 1/2-loop of VKOR, with a mixed disulphide bridge as an intermediate. Third, the loop cysteines reduce the CXXC motif of VKOR. Finally, the disulphide in this CXXC motif is reformed by reduction of the quinone. The net effect Warfarin resistance mutations in mammalian VKOR located close to the bound quinone or elsewhere are indicated as blue or green ovals, respectively. The labels refer to positions in human VKOR. b, Mutations indicated in blue in a are mapped into the Synechococcus structure, on the basis of sequence alignment ( Supplementary  Fig. 2 ). Some TM segments are removed for clarity. Labels refer to the residue in Synechococcus VKOR, followed by the residue and its position in human VKOR. The positions V29, R33 and D36 are in a helical extension of TM1, but their location is somewhat uncertain because of alignment ambiguities. The experimental electron density map is contoured at 1s (blue) and 3.5s (red). Note the strong electron density between Cys 130 and Cys 133, indicative of a disulphide bridge (in green), as well as between Cys 133 and the C1 position of the quinone. TM3 and the 1/2-helix are shown without electron density for orientation. b, Surface representation of the binding pocket for the quinone (in red), viewed from the side. TM5 was removed for clarity. Note the cleft between TMs 2 and 3, blocked only by the side chains shown in purple, which could provide a lateral exit for the quinone into lipid. The lower part of the membrane is not shown.
would be the movement of reducing equivalents from cysteines in newly synthesized proteins to the quinone.
One implication of the structure is that a major conformational change is required to allow electrons to flow from the Trx-like domain to the quinone. Specifically, the amphipathic 1/2-helix must move out of the way, perhaps by sliding parallel to the plane of the membrane, to allow Cys 56 in the loop to gain access to Cys 130 of the CXXC motif. In the resting state, the 1/2-helix would shield the active site, preventing it from non-selectively oxidizing proteins in the periplasm.
Our model assumes that during the reaction cycle, a covalent bond is formed between the quinone and Cys 133, consistent with the observed continuous electron density between them and with a previously proposed catalytic mechanism 21 . Cys 133 is located on the side of the quinone ring, a geometry that probably facilitates electron transfer to the aromatic systems and has been observed for the soluble FAD-containing thiol oxidases Ero1p 22 and Erv2p 23 . Interestingly, the quinone seems to interact with Cys 133 at an early stage of the redox process, when Cys 133 is still disulphide bonded with Cys 130 (Fig. 4, boxed intermediate, as represented by our structure). We propose that once the quinone is fully reduced, it would no longer be covalently linked to Cys 133 and could then exit the binding pocket into the lipid phase through the cleft between TM2 and TM3 (Fig. 2b) . The quinone would thus be exchanged during each round of the redox cycle.
Electron transfer in vitro
To verify the proposed electron transfer pathway, we established a reconstituted system for vitamin K-dependent oxidative protein folding. The purified Synechococcus sp. protein, containing both the VKOR and Trx-like domains, was incubated with reduced RNase A, and disulphide bridge formation was assayed by protection from a cysteine-modifying reagent. The cysteines in RNase A were oxidized only when vitamin K was added (Fig. 5a, lane 10 versus 12) . Other quinones, such as ubiquinone Q1 and menaquinone (vitamin K2), were also active (data not shown). Dilution experiments show that a single VKOR molecule can catalyse the oxidation of ,500 cysteines (Fig. 5b) . Mutation of any of the cysteines in the electron transfer pathway (Cys 209 and Cys 212 in the Trx-like domain and Cys 50, Cys 56, Cys 130 and Cys 133 in VKOR; Fig. 4 ) abolish disulphide bridge formation (Fig. 5c ). The activity of the bacterial VKOR homologue could also be demonstrated when the reduction of vitamin K was followed with a fluorometric assay. Again, with a, Purified Synechococcus protein, containing the VKOR and Trx-like domains, was incubated with reduced, denatured RNase A and vitamin K1 (Vit K1) (lanes 9, 10). The reaction was quenched with AMS, which modifies free sulphydryl groups. Samples were analysed by SDS-PAGE and Coomassie staining. Controls were performed without Vit K1 (in ethanol, EtOH) or VKOR, as indicated. RNase A was also oxidized with glutathione (GSH/GSSG) (lanes 3,4) . b, As in a, but with VKOR serially diluted. c, As in a, but with wild type (WT) or mutants in cysteines in the predicted electron transfer pathway ( Fig. 4) . d, As in c, except reduction of Vit K1 was followed in a fluorometer, using reduced RNase or dithiothreitol (DTT) as reductant. Error bars represent standard error of mean instrumental fluorescence variation.
reduced RNase A as substrate, none of the cysteine mutants was active (Fig. 5d ). However, with dithiothreitol (DTT) as reductant, only the active site mutants Cys130Ala and Cys133Ala were inactive. Thus, DTT can directly reduce the active site, bypassing the other cysteines. These results argue that under physiological conditions, the Trx-like domain reduces the loop cysteines of VKOR, which in turn reduce the active site cysteines. Warfarin only inhibited the reaction at high concentrations (data not shown), but ferulenol, a close analogue, was almost as potent as with the mammalian enzyme (half-maximum inhibition 0.2 mM versus 0.1 mM) (ref. 24 ; Supplementary Fig. 10 ). These data again emphasize the similarities between the bacterial and mammalian enzymes. It should be noted, however, that the mammalian VKOR catalyses both the reduction of vitamin K epoxide to the quinone, and from the quinone to the hydroquinone, using the same redox-active cysteines 25 (Fig. 4) , whereas the bacterial VKOR homologues might perform only the quinone to hydroquinone conversion. In fact, we have not been able to detect reduction of vitamin K epoxide by the enzyme from Synechococcus sp. (data not shown), and quinone epoxides have not been described in bacteria.
Pathways of disulphide formation
It is revealing to compare the VKOR pathway with the other known system of disulphide bridge formation in bacteria. Instead of VKOR, many bacteria possess DsbB, a sequence-unrelated membrane protein that shuttles electrons from the periplasmic, Trx-like DsbA protein to a quinone [26] [27] [28] . Like VKOR, DsbB contains four TM segments and a quinone 14, [29] [30] [31] . DsbB also has an active site CXXC motif, a long loop containing two shuttle cysteines, and an amphipathic helix (3/4-helix) within this loop. A comparison of the structures shows that the TM segments of DsbB form a four-helix bundle that is similar to that of VKOR ( Fig. 6a ; left and middle panels). In both cases, the helices are arranged in a clock-wise manner when viewed from the periplasm, and encircle the quinone. However, the shuttle cysteines in DsbB are located in a loop between TMs 3 and 4, rather than between TMs 1 and 2, and the CXXC motif is present on the periplasmic side of TM2, rather than in TM4. In both enzymes, an amphipathic helix, the 1/2-helix in VKOR and the 3/4-helix in DsbB, sits at the membrane surface and may serve to anchor a loop cysteine close to the active site CXXC motif. The quinone is located at about the same position in VKOR and DsbB 30 (Fig. 6a; right panel) . We postulate that in wildtype DsbB, Cys 44 would interact with the quinone, similarly to Cys 133 in VKOR, even when the CXXC motif is oxidized. As with VKOR, the hydroquinone generated during each redox cycle might lose its interaction with the cysteine and be laterally released into lipid, although an alternative model in which the quinone is permanently bound has also been proposed 32 .
The structural similarities indicate that the electron transfer mediated by VKOR and DsbB occurs by a common general pathway. However, whereas the amphipathic 1/2-helix of VKOR follows the loop cysteines (Fig. 6b, c, left panel) and must relocate to allow electron transfer from the Trx-like domain to the quinone, DsbB does not require major conformational changes. DsbB's amphipathic 3/4-helix separates the two loop cysteines, which are only able to interact because of the unusual, peripheral location of the helix with respect to the four-helix bundle (Fig. 6b, c, right panel) . The reactive cysteines are all lined up (Cys 30 in DsbA, Cys 104, Cys 41 and Cys 44 in DsbB), allowing unimpeded electron transfer from the Trx-like domain to the quinone 30, 31 .
The two pathways of disulphide bridge formation in bacteria also share similarities with those in eukaryotes. Although the oxidases Ero1p and Erv2p are present in the ER lumen, rather than integrated into the membrane, they also contain four helices in association with a cofactor (FAD), a loop with shuttling cysteines, and an active site CXXC motif 22, 23 . Thus, disulphide bridge formation seems to generally use similarly structured components for electron transfer, with VKOR representing the newest class of sulphydryl oxidases.
METHODS SUMMARY
The codon-optimized VKOR gene from Synechococcus sp. was expressed with a His tag in E. coli and the protein was purified by Ni-affinity and gel-filtration chromatography in 0.05% DDM. Crystals were obtained by the hanging drop diffusion method and frozen in liquid nitrogen. To obtain heavy atom derivatives, the crystals were soaked with mercury, platinum or lead compounds. Phases were obtained by the MIR (multiple isomorphous replacement) method and improved by solvent flattening. The Trx-like domain (amino acids 186 to 283) was expressed in E. coli, purified and crystallized. SAD (single-wavelength anomalous dispersion) phases were calculated using heavy atom sites found by the direct method, and the model was built and refined automatically. This structure was docked into the density map of the full-length protein. The final model of the full-length protein was manually built and refined to R work and R free factors of 24.6% and 30.5%, respectively. The structure factors and coordinates were deposited in the protein data bank (accession code 3KP9 for the full-length protein and accession code 3KP8 for the Trx-like domain).
Disulphide bridge formation in RNase A was assayed by combining purified VKOR protein (0.5 mM) with reduced, denatured RNase A (15 mM) and vitamin K1 quinone (100 mM); the reaction was quenched by addition of 53 non-reducing SDS buffer supplemented with 50 mM AMS (4-acetamido-49-maleimidylstilbene-2,29-disulphonic acid). Reduction of vitamin K1 (300 mM) was assayed fluorometrically by excitation at 250 nm and following emission at 430 nm. The reaction was 
